Healthcare >> CEO Interviews >> November 2, 2009
Cynthia M. Butitta is Telik's Chief Operating Officer and Chief Financial Officer. She joined the company in 1998 as Chief Financial Officer. Ms. Butitta has extensive financial and operational experience in the biotechnology and high technology industries. Prior to joining Telik, she provided financial and consulting services to biotechnology companies as a Partner in Altair Capital Associates, and she also operated Butitta Consulting Services. From 1995 to 1997, Ms. Butitta was Vice President of Finance and Administration, and Chief Financial Officer for Connetics, Inc. Previously, she was Director of Sales Operations for MIPS Computer Systems, Inc., and she has held senior level positions in information technology, contract planning and manufacturing in the high technology industry. Ms. Butitta holds a B.S. in business and accounting from Edgewood College in Madison, Wis., and an MBA in finance from the University of Wisconsin, Madison.
Dr. Michael M. Wick, M.D., Ph.D., is Chairman and Chief Executive Officer of Telik, Inc. He joined Telik in 1997 from CV Therapeutics, Inc., where he was Senior Vice President of Research and Development. Prior to joining CV Therapeutics, Dr. Wick was Executive Director of Oncology/Immunology and Clinical Research at Lederle Laboratories, a division of American Cyanamid, where he also directed the Cyanamid/Immunex joint oncology research program. Dr. Wick began his career at Harvard Medical School, where he was an Associate Professor. He also was Chief of the Melanoma Clinic and Laboratory of Molecular Dermatological Oncology at the Dana Farber Cancer Institute. Dr. Wick holds a Ph.D. in chemistry from Harvard University and an M.D. from Harvard Medical School. Profile
TWST: Please begin with a brief overview of the history and evolution of Telik.
Dr. Wick: Telik (TELK)is a cancer-focused biotechnology company that distinguishes itself by having discovered its own
